Table 5.
AE Non-COVID up to 1 year COVID-19 vaccine clinical trial.
| Study | Number of Subjects | Overall AE Non-Covid | AE Grade ≥3 | Follow-Up Period |
|---|---|---|---|---|
| AV-COVID-19 | 138 (phase II) | 16,67% | 0.72% | 365 days |
| Astrazeneca ChAdOx1 nCoV-19 (9) | 17.662 (phase III) | NA | 0.4% | 135 days |
| J&J Ad26.COV2.S (4) | 19.113 (phase III) | NA | 1% | 294 days |
| Moderna mRNA-1273 (10) | 14.287 (phase III) | NA | 1.3% | 260 days |
| Pfizer BNT162b2 (11) | 21.650 (phase III) | NA | 1.2% | 238 days |
| Sinovac CoronaVac (12) | 6.646 (phase III) | NA | 0.1% | 120 days |
| Zififax ZF2001 (13) | 12.625 (phase III) | NA | 1.6% | 390 days |
NA, Data not available.
* Reported data are AE phase III clinical trials in the treatment group.
The meaning of bold values are the result from our study.